Nick Leschly, bluebird CEO at JPM20 (Jeff Rumans)
May 11, 2020 10:19 AM EDTUpdated 10:54 AM
Deals
FDA+

Blue­bird takes $200M pay­out from Bris­tol My­ers as Covid-19, BLA de­lays force ex­ecs to bring out the bud­get ax

Jason Mast

Editor

Covid-19 is tak­ing its toll on one of the in­dus­try’s flashiest biotechs.

In their Q1 fil­ing, blue­bird bio dis­closed a se­ries of changes de­signed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times